Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImmunoCellular Therapeutics Ltd.

www.imuc.com

Latest From ImmunoCellular Therapeutics Ltd.

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth

Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.

Financing Business Strategies

Galena, ImmunoCellular Caught Up In US SEC Clampdown On Fraudulent Stock Promotions

Four biopharma firms allegedly paid writers to post positive articles about their stocks that were merely "paid advertisements"; in settlement, former CEOs of Galena and ImmunoCellular barred from being officer or director for five years and ordered to pay $1.3m and $2.9m, respectively.

Legal Issues Regulation

Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?

The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.

Clinical Trials

FINANCE ROUNDUP: Will VC Be Last Man Standing If Biotech Bubble Bursts?

The bad news about the rapid rise in biotechnology company valuations? It will end eventually. The good news? While initial public offerings may no longer be an option for some pre-commercial companies to fund drug development, several venture capital investors recently raised new funds to back biotech startups and support follow-on financing rounds.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Optical Molecular Imaging Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ImmunoCellular Therapeutics Ltd.
  • Senior Management
  • David Fractor, VP, Fin.
    John S Yu, MD, CSO
    Steven Swanson, PhD, SVP, Research
  • Contact Info
  • ImmunoCellular Therapeutics Ltd.
    Phone: (818) 264-2300
    23622 Calabasas Rd.
    Ste. 300
    Calabasas, CA 91302
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register